Gefitinib and erlotinib in metastatic non-small cell lung cancer: A meta-analysis of toxicity and efficacy of randomized clinical trials

Oncologist

Volumn 20, Issue 4, 2015, Pages 400-410

  Burotto, Mauricio ^a   Manasanch, Elisabet E ^b   Wilkerson, Julia ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Afatinib; Erlotinib; Gefitinib; Lung cancer; Tyrosine kinase inhibitors

Indexed keywords

ERLOTINIB; GEFITINIB; AFATINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ANEMIA; ANOREXIA; ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG EFFICACY; FATIGUE; HUMAN; INFORMATION PROCESSING; META ANALYSIS; METASTASIS; MUCOSA INFLAMMATION; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PARONYCHIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MORTALITY; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; ERLOTINIB HYDROCHLORIDE; HUMANS; LUNG NEOPLASMS; PUBLICATION BIAS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84927660507     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0154     Document Type: Article

References (71)

1. Siegel R, MaJ, Zou Z et al. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Chen X, ZhuQ, Zhu L et al. Clinical perspective of afatinib in non-small cell lung cancer. Lung Cancer 2013; 81: 155-161.
3. Goldstraw P, Ball D, Jett JR et al. Non-small-cell lung cancer. Lancet 2011; 378: 1727-1740.
4. Thomas A, Rajan A, Lopez-Chavez A et al. From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol 2013; 24: 577-585.
5. Li T, Kung HJ, Mack PC et al. Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies. J Clin Oncol 2013; 31: 1039-1049.
6. Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. CurrMedRes Opin 2006; 22: 561-573.
7. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
8. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-smallcell lung cancer. N Engl J Med 2010; 363: 1693-1703.
9. ShawAT, KimDW, MehraRet al. Ceritinib in ALKrearranged non-small-cell lung cancer. N Engl JMed 2014; 370: 1189-1197.
10. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
11. Cohen MH, Williams GA, Sridhara R et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10: 1212-1218.
12. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
13. FDA alert for healthcare professionals: Gefitinib (marketed as Iressa). Available at http://www. fda. gov/downloads/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ucm126182. pdf. Accessed January 18, 2015.
14. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008; 372: 1809-1818.
15. FDA approves new drug for the most common type of lung cancer drug shows survival benefit. Available at http://www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108378. htm. Accessed January 18, 2015.
16. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl JMed 2005; 353: 123-132.
17. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521-529.
18. FDA approval for erlotinib hydrochloride. Available at http://www. cancer. gov/cancertopics/druginfo/fda-erlotinib-hydrochloride. Accessed January 18, 2015.
19. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
20. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
21. Fukuoka M, Yano S, Giaccone G et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 2003; 21: 2237-2246.
22. GiacconeG, HerbstRS, ManegoldCetal. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004; 22: 777-784.
23. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl JMed 2010; 362: 2380-2388.
24. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with nonsmall-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
25. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): Amulticentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
26. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
27. Sequist LV, Yang JC, YamamotoNet al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-3334.
28. Hirsch FR, Bunn PA Jr. A new generation of EGFR tyrosine-kinase inhibitors in NSCLC. Lancet Oncol 2012; 13: 442-443.
29. Lee CK, Brown C, Gralla RJ et al. Impact of EGFR inhibitor in non-small cell lung cancer on progressionfree and overall survival: Ameta-analysis. JNatl Cancer Inst 2013; 105: 595-605.
30. Chen X, Liu Y, RøeODet al. Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: A systematic review. PLoS One 2013; 8: e59314.
31. Fan WC, Yu CJ, Tsai CM et al. Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: A retrospective multicenter study. J Thorac Oncol 2011; 6: 148-155.
32. Murphy M, Stordal B. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic review. Drug Resist Updat 2011; 14: 177-190.
33. Paz-Ares L, Soulières D, Melezínek I et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: Pooled analysis. J Cell Mol Med 2010; 14: 51-69.
34. Petrelli F, Borgonovo K, Cabiddu M et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: Ameta-analysis of 13 randomized trials. Clin Lung Cancer 2012; 13: 107-114.
35. Shao YY, Shau WY, Lin ZZ et al. Comparison of gefitiniband erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. Eur J Cancer 2013; 49: 106-114.
36. Miller VA, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol 2012; 13: 528-538.
37. Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213-222.
38. Schwarzer G. Meta-analysis with R. R package version 2. 5-1. 2013. Available at http://cran. r-project. org/web/packages/meta/index. html. Accessed March 6, 2015.
39. Viechtbauer W. Conducting meta-analyses in R with themetafor package. J Stat Softw 2010; 36: 1-48.
40. Sun JM, Lee KH, Kim SW et al. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): An open-label, phase 3 trial. Cancer 2012; 118: 6234-6242.
41. Cufer T, Vrdoljak E, Gaafar R et al. Phase II, open-label, randomizedstudy (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006; 17: 401-409.
42. Lee DH, Park K, Kim JH et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010; 16: 1307-1314.
43. Goss G, Ferry D, Wierzbicki Ret al. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced nonsmall-cell lung cancer and poor performance status. J Clin Oncol 2009; 27: 2253-2260.
44. Morère JF, Bréchot JM, Westeel V et al. Randomizedphase II trialofgefitinib or gemcitabineordocetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer 2010; 70: 301-307.
45. Kelly K, Chansky K, Gaspar LE et al. Phase III trial ofmaintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stageIIInon-small-cell lungcancer: SWOG S0023. J Clin Oncol 2008; 26: 2450-2456.
46. Gaafar RM, Surmont VF, Scagliotti GV et al. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer 2011; 47: 2331-2340.
47. Zhang L, Ma S, Song X et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): A multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012; 13: 466-475.
48. Takeda K, Hida T, Sato T et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: Results of awest Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010; 28: 753-760.
49. Ahn MJ, Yang JC, Liang J et al. Randomized phase II trial of first-line treatmentwith pemetrexedcisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer 2012; 77: 346-352.
50. Crinò L, Cappuzzo F, Zatloukal P et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): A randomized, phase II study. J Clin Oncol 2008; 26: 4253-4260.
51. Ciuleanu T, Stelmakh L, Cicenas S et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012; 13: 300-308.
52. Kelly K, Azzoli CG, ZatloukalPet al. Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinumbased therapy. J Thorac Oncol 2012; 7: 1041-1048.
53. Gridelli C, Ciardiello F, Gallo C et al. First-line erlotinib followedby second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial. J Clin Oncol 2012; 30: 3002-3011.
54. Pérol M, Chouaid C, Pérol D et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy inadvanced non-small-cell lung cancer. J Clin Oncol 2012; 30: 3516-3524.
55. Chen YM, Tsai CM, Fan WC et al. Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older. J Thorac Oncol 2012; 7: 412-418.
56. Stinchcombe TE, Peterman AH, Lee CB et al. A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age$70 years) with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2011; 6: 1569-1577.
57. LeCaer H, Barlesi F, Corre R et al. Amulticentre phase II randomised trial of weekly docetaxel/gemcitabine followed byerlotinibonprogression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study). Br J Cancer 2011; 105: 1123-1130.
58. LeCaer H, Greillier L, Corre R et al. A multicenterphase IIrandomizedtrial ofgemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study). Lung Cancer 2012; 77: 97-103.
59. Cataldo VD, Gibbons DL, Pérez-Soler R et al. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl JMed 2011; 364: 947-955.
60. Hotta K, Kiura K, Takigawa N et al. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: The Okayama Lung Cancer Study Group experience. J Thorac Oncol 2010; 5: 179-184.
61. Ling J, Fettner S, Lum BL et al. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs 2008; 19: 209-216.
62. Cantarini MV, McFarquhar T, Smith RP et al. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: Results of a randomized, open-label, three-period crossover study in healthy volunteers. Clin Ther 2004; 26: 1630-1636.
63. Li J, ZhaoM, He P et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007; 13: 3731-3737.
64. Bronte G, Rolfo C, Giovannetti E et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol 2013; 89: 300-313.
65. Yun CH, Boggon TJ, Li Y et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11: 217-227.
66. Garassino MC, Martelli O, Broggini M et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer andwild-typeEGFRtumours (TAILOR): Arandomised controlled trial. Lancet Oncol 2013; 14: 981-988.
67. Gridelli C, Felip E. Targeted therapies development in thetreatment ofadvancednonsmallcell lung cancer. J Biomed Biotechnol 2011; 2011: 415641.
68. Langer CJ. Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: Is afatinib better or simply newer? J Clin Oncol 2013; 31: 3303-3306.
69. Afatinib. Available at http://www. fda. gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm360574. htm. Accessed January 18, 2015.
70. KatakamiN, Atagi S, Goto K et al. LUX-Lung 4: A phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013; 31: 3335-3341.
71. Yang JC, Wu YL, SchulerMet al. Afatinib versus cisplatin-based chemotherapy for EGFR mutationpositive lung adenocarcinoma (LUX-Lung 3 and LUXLung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141-151.